1.Date of occurrence of the event:2021/12/01
2.Company name:ONENESS BIOTECH CO., LTD.
3.Relationship to the Company (please enter ”head office” or
”subsidiaries”):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:The Company has been informed by the patent agency
that a Taiwan patent titled ”TOPICAL FORMULATION FOR PROMOTING WOUND
HEALING” has been granted on the new drug Fespixon cream
(Research code: ON101) under the patent number I746597.
6.Countermeasures:None
7.Any other matters that need to be specified:
(1)The new drug, Fespixon cream has been granted many international patents.
The development of new drugs is lengthy so many new drugs are faced with
expiring patent protection shortly after their market approval, which
results in loss of market exclusivity. The Company has filed a new patent
for the topical formulation of Fespixon cream with innovative and
efficacious scientific data and has been granted such patent in the US,
the largest market this February, and subsequently also granted in Russia,
Mexico and Taiwan.
(2)The patent of the topical formulation of Fespixon new drug has been filed
in major countries or regions of the global market. The granted patent
term remains valid till 2037-2038. Extension of the patent term can be
applied for up to 5 years after the product is approved to be marketed.
(3)During the term of the granted patent, Fespixon cream will be protected
against any generic competition.